Form 4: Lemaitre Vascular Director John James O'Connor Reports Acquisition of Dividend Equivalent Rights

Director John James O'Connor reports the acquisition of dividend equivalent rights related to restricted stock unit and performance share unit awards.

Summary

• John James O'Connor, a director of Lemaitre Vascular Inc., reported the acquisition of dividend equivalent rights on May 30, 2024.
• These rights are associated with previously granted restricted stock unit (RSU) and performance share unit (PSU) awards.
• The dividend equivalent rights vest proportionately with the underlying awards and are economically equivalent to shares of Lemaitre Vascular's common stock.
• The acquisitions include 0.402 rights related to a 2021 RSU award, 0.8146 rights related to a 2022 RSU award, 0.8146 rights related to a 2022 PSU award, and 1.0426 rights related to a 2023 RSU award.
• Following these transactions, O'Connor directly owns 7.3163, 6.7657, 5.777, and 2.2771 dividend equivalent rights respectively.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction related to executive compensation. It's neutral in sentiment as it simply reports the acquisition of dividend equivalent rights.

Positives

• The acquisition of dividend equivalent rights suggests continued alignment of the director's interests with those of the shareholders.
• The vesting of these rights is tied to the vesting of underlying RSU and PSU awards, incentivizing long-term performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The acquisition of dividend equivalent rights aligns the director's interests with shareholders, potentially encouraging value creation.

Key Dates